Journals / Anadolu Kardiyoloji Dergisi / 2008 / Cilt: 8 - Sayı: 6

Gün aşırı 20 mg atorvastatin tedavisinin serum LDL-kolesterolü ve düksek duyarlı C-reaktif protein düzeyleri üzerine etkisinin günlük 20 mg atorvastatin tedavisi ile karşılaştırılması

The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels

Pages
407–412
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The LDLcholesterol levels of the group receiving 20 mg atorvastatin every day was reduced by %41 by the end of 1 month (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In this study, we aimed at comparing the effects of standard once daily 20 mg atorvastatin treatment with that of atorvastatin 20 mg administered every other day on serum lipids and high sensitive C-reactive protein (hs-CRP) levels.
📊
Key Findings & Data:Methods: Sixty-one patients with serum total cholesterol levels of above 200 mg/dl and low density lipoprotein (LDL) - cholesterol levels of above 130 mg/dl were included in this prospective, randomized study.
💡
Conclusion & Impact:The LDLcholesterol levels of the group receiving 20 mg atorvastatin every day was reduced by %41 by the end of 1 month (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: In this study, we aimed at comparing the effects of standard once daily 20 mg atorvastatin treatment with that of atorvastatin 20 mg administered every other day on serum lipids and high sensitive C-reactive protein (hs-CRP) levels. Methods: Sixty-one patients with serum total cholesterol levels of above 200 mg/dl and low density lipoprotein (LDL) - cholesterol levels of above 130 mg/dl were included in this prospective, randomized study. The patients were randomized into daily treatment of 20 mg atorvastatin (standard treatment) and 20 mg atorvastatin every other day (every other day treatment) groups. Before the treatment and at each visit, serum lipids and hs-CRP levels of all the patients were measured. Statistical analyses were performed Chi-square, unpaired t and two-way repeated measurements ANOVA tests.Results: In the every other day treatment group, there was a 36.1% reduction in LDL-cholesterol levels by the end of first month (p0.05). The LDLcholesterol levels of the group receiving 20 mg atorvastatin every day was reduced by %41 by the end of 1 month (p

Özet

Amaç: Bu çalışmada her gün alınan 20 mg atorvastatin tedavisi ile gün aşırı alınan 20 mg atorvastatin tedavisinin serum lipitleri ve yüksek duyarlı C-reaktif protein (CRP) düzeyleri üzerine etkilerinin karşılaştırılması amaçlanmıştır. Yöntemler: Bu prospektif randomize çalışmaya serum total kolesterolü 200 mg/dl, düşük yoğunluklu lipoprotein (LDL) kolesterolü ise 130 mg/dl’nin üzerinde olan 61 hasta alınmıştır. Hastalar günlük ve gün aşırı 20 mg atorvastatin alan iki gruba randomize edildiler. Tedavi öncesi ve her hastane gelişinde serum lipid parametreleri ve yüksek duyarlı CRP düzeyleri ölçüldü. İstatistiksel analizler Ki-kare, eşleştirilmemiş t ve iki-yönlü ANOVA testleri ile yapıldı. Bulgular: Gün aşırı ilaç alan grupta birinci ayın sonunda LDL kolesterol düzeylerinde %36.1 azalma izlendi (p0.05). Her gün ilaç alan grupta ise birinci ayın sonunda LDL düzeylerinde %41 oranında azalma izlendi (p

🔖

Cite This Article

CANBAY, A., KELEŞ, T., DURMAZ, T., AYDOĞDU, S., ÖZDEMİR, Ö., DİKER, E., ŞAHİN, D., BAYRAM, N. A., KAYHAN, T. (2022). Gün aşırı 20 mg atorvastatin tedavisinin serum LDL-kolesterolü ve düksek duyarlı C-reaktif protein düzeyleri üzerine etkisinin günlük 20 mg atorvastatin tedavisi ile karşılaştırılması. Anadolu Kardiyoloji Dergisi, Cilt: 8 - Sayı: 6, 407–412. https://ajindex.com/articles/437080

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Downs JR, Clearfield M, Weis E, Whiyney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-22
  2. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: Scandinavian Simvastatin Survival Study. Lancet 1994; 344: 1383-9
  3. Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57
  4. Schönbeck U, Libby P. Inflammation, immunity and HMG-CoA reductase inhibitors. Statins as antiinflammatory agents? Circulation 2004; 109 (suppl II): II18-II26
  5. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004; 109 (suppl II): II2-II10
  6. Matalka MS, Ravnan MC, Deedwania MD. Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day versus Daily Dosing of Atrovastatin Study (ADDAS). Am Heart J 2002; 144: 674-7
  7. Jafari M, Ebrahimi R, Ahmadi-Kashani M, Balian H, Bashir M. Efficacy of alternate-day dosing versus daily dosing of atorvastatin. J Cardiovasc Phramacol Ther 2003; 8:123-6
  8. Copher HR, Steward RD. Daily dosing versus alternate-dosing of simvastatin in patients with hypercholesterolemia. Pharmacotherapy 2002; 22: 110-6
  9. Piamsomboon C, Laothavorn P, Saguonwong S, Chatloong B, Nasawadi C, Tanprasert P. Efficacy and safety of atorvastatin 10 mg every other day in hypercholesterolemia. J Med Assoc Thai 2002; 8: 297-300
  10. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation and Treatment of High Blood Cholesterol in adults (Adult Panel Treatment III) final report. Circulation 2002; 106: 3143-321
  11. Friedewald WT, Levy RI, Frederickson DS. Estimation of concentration of low-density lipoprotein cholesterol in plasma, without use of preoperative ultracentrifuge. Clin Chem 1972; 18: 499-502
  12. Lea AP, McTavisch D. Atorvastatin: a review of its pharmacology and therapeutic potential in the management of hyperlipidemias. Drugs 1997; 53: 828-47
  13. Iliff RD. Weekly versus daily dosing of atorvastatin. J Fam Pract 2002; 51: 365-6
  14. Jones PH. Compar